Intensified-Dose Chemotherapy in Combination With Gemtuzumab-Ozogamicin for the Treatment of Favorable-Risk Acute Myeloid Leukemia (AML)
Chemotherapy has been the standard of treatment for acute myeloid leukemia (AML). With the emergence of new therapies for AML like gemtuzumab-ozogamicin and FLT3 inhibitors, such as sorafenib, midostaurin, and gilteritinib, the optimal dose of chemotherapy and safety profile in different age groups...
Gespeichert in:
| Veröffentlicht in: | Curēus (Palo Alto, CA) CA), 2022-06, Vol.14 (6) |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 6 |
| container_start_page | |
| container_title | Curēus (Palo Alto, CA) |
| container_volume | 14 |
| creator | Vegunta, Rathnamitreyee Harel, Ronen Steinberg, Amir |
| description | Chemotherapy has been the standard of treatment for acute myeloid leukemia (AML). With the emergence of new therapies for AML like gemtuzumab-ozogamicin and FLT3 inhibitors, such as sorafenib, midostaurin, and gilteritinib, the optimal dose of chemotherapy and safety profile in different age groups when combined with these new therapies is yet to be established. There are limited data on the treatment of AML by combining intensified daunorubicin (doses of 90 mg/m2) with gemtuzumab-ozogamicin (GO). We report a young adult with favorable-risk AML treated with daunorubicin at a dose of 90 mg/m2 combined with GO, who had a complete response after induction but had a profound nadir of platelet count after induction and consolidation. |
| doi_str_mv | 10.7759/cureus.26240 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9308398</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2696787498</sourcerecordid><originalsourceid>FETCH-LOGICAL-c243t-94fd04755cea1836ac4e3a260d1035666f04913f883d71dc60f1b23fd2ac8bb23</originalsourceid><addsrcrecordid>eNpVUV1LHDEUDcVSZetbf0CgLwodm4-ZTOalsKz1A1aEYuljyGRu3Ohmss2HsP4Cf7ajK9I-3QP33HMP5yD0hZKTtm2676ZEKOmECVaTD-iAUSErSWW99w_eR4cp3RFCKGkZackntM8b2Uku6QF6uhwzjMlZB0N1GhLgxQp8yCuIerPFbsSL4Hs36uzCiP-4vMLn4HN5LF731fVjuNXemYlmQ8TTFb6JoLOHMeNg8Zl-CFH3a6h-uXSP56ZkwFdbWAc34CWUe_BO46P51fL4M_po9TrB4ducod9nP28WF9Xy-vxyMV9WhtU8V11tB1K3TWNAU8mFNjVwzQQZKOGNEMKSuqPcSsmHlg5GEEt7xu3AtJH9hGbox053U3oPg5mcRr1Wm-i8jlsVtFP_b0a3UrfhQXWcSD6lNkNf3wRi-FsgZXUXShwnz4qJTrSyrV9Z33YsE0NKEez7B0rUS3VqV516rY4_A4PHjhc</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2696787498</pqid></control><display><type>article</type><title>Intensified-Dose Chemotherapy in Combination With Gemtuzumab-Ozogamicin for the Treatment of Favorable-Risk Acute Myeloid Leukemia (AML)</title><source>PubMed Central Open Access</source><source>PubMed Central</source><creator>Vegunta, Rathnamitreyee ; Harel, Ronen ; Steinberg, Amir</creator><creatorcontrib>Vegunta, Rathnamitreyee ; Harel, Ronen ; Steinberg, Amir</creatorcontrib><description>Chemotherapy has been the standard of treatment for acute myeloid leukemia (AML). With the emergence of new therapies for AML like gemtuzumab-ozogamicin and FLT3 inhibitors, such as sorafenib, midostaurin, and gilteritinib, the optimal dose of chemotherapy and safety profile in different age groups when combined with these new therapies is yet to be established. There are limited data on the treatment of AML by combining intensified daunorubicin (doses of 90 mg/m2) with gemtuzumab-ozogamicin (GO). We report a young adult with favorable-risk AML treated with daunorubicin at a dose of 90 mg/m2 combined with GO, who had a complete response after induction but had a profound nadir of platelet count after induction and consolidation.</description><identifier>ISSN: 2168-8184</identifier><identifier>EISSN: 2168-8184</identifier><identifier>DOI: 10.7759/cureus.26240</identifier><identifier>PMID: 35898381</identifier><language>eng</language><publisher>Palo Alto: Cureus Inc</publisher><subject>Bone marrow ; Case reports ; Chemotherapy ; Hematology ; Inhibitor drugs ; Leukemia ; Monoclonal antibodies ; Mutation ; Oncology ; Patients ; Remission (Medicine) ; Targeted cancer therapy ; Thrombocytopenia</subject><ispartof>Curēus (Palo Alto, CA), 2022-06, Vol.14 (6)</ispartof><rights>Copyright © 2022, Vegunta et al. This work is published under https://creativecommons.org/licenses/by/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Copyright © 2022, Vegunta et al. 2022 Vegunta et al.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c243t-94fd04755cea1836ac4e3a260d1035666f04913f883d71dc60f1b23fd2ac8bb23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9308398/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9308398/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,724,777,781,882,27905,27906,53772,53774</link.rule.ids></links><search><creatorcontrib>Vegunta, Rathnamitreyee</creatorcontrib><creatorcontrib>Harel, Ronen</creatorcontrib><creatorcontrib>Steinberg, Amir</creatorcontrib><title>Intensified-Dose Chemotherapy in Combination With Gemtuzumab-Ozogamicin for the Treatment of Favorable-Risk Acute Myeloid Leukemia (AML)</title><title>Curēus (Palo Alto, CA)</title><description>Chemotherapy has been the standard of treatment for acute myeloid leukemia (AML). With the emergence of new therapies for AML like gemtuzumab-ozogamicin and FLT3 inhibitors, such as sorafenib, midostaurin, and gilteritinib, the optimal dose of chemotherapy and safety profile in different age groups when combined with these new therapies is yet to be established. There are limited data on the treatment of AML by combining intensified daunorubicin (doses of 90 mg/m2) with gemtuzumab-ozogamicin (GO). We report a young adult with favorable-risk AML treated with daunorubicin at a dose of 90 mg/m2 combined with GO, who had a complete response after induction but had a profound nadir of platelet count after induction and consolidation.</description><subject>Bone marrow</subject><subject>Case reports</subject><subject>Chemotherapy</subject><subject>Hematology</subject><subject>Inhibitor drugs</subject><subject>Leukemia</subject><subject>Monoclonal antibodies</subject><subject>Mutation</subject><subject>Oncology</subject><subject>Patients</subject><subject>Remission (Medicine)</subject><subject>Targeted cancer therapy</subject><subject>Thrombocytopenia</subject><issn>2168-8184</issn><issn>2168-8184</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNpVUV1LHDEUDcVSZetbf0CgLwodm4-ZTOalsKz1A1aEYuljyGRu3Ohmss2HsP4Cf7ajK9I-3QP33HMP5yD0hZKTtm2676ZEKOmECVaTD-iAUSErSWW99w_eR4cp3RFCKGkZackntM8b2Uku6QF6uhwzjMlZB0N1GhLgxQp8yCuIerPFbsSL4Hs36uzCiP-4vMLn4HN5LF731fVjuNXemYlmQ8TTFb6JoLOHMeNg8Zl-CFH3a6h-uXSP56ZkwFdbWAc34CWUe_BO46P51fL4M_po9TrB4ducod9nP28WF9Xy-vxyMV9WhtU8V11tB1K3TWNAU8mFNjVwzQQZKOGNEMKSuqPcSsmHlg5GEEt7xu3AtJH9hGbox053U3oPg5mcRr1Wm-i8jlsVtFP_b0a3UrfhQXWcSD6lNkNf3wRi-FsgZXUXShwnz4qJTrSyrV9Z33YsE0NKEez7B0rUS3VqV516rY4_A4PHjhc</recordid><startdate>20220623</startdate><enddate>20220623</enddate><creator>Vegunta, Rathnamitreyee</creator><creator>Harel, Ronen</creator><creator>Steinberg, Amir</creator><general>Cureus Inc</general><general>Cureus</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope></search><sort><creationdate>20220623</creationdate><title>Intensified-Dose Chemotherapy in Combination With Gemtuzumab-Ozogamicin for the Treatment of Favorable-Risk Acute Myeloid Leukemia (AML)</title><author>Vegunta, Rathnamitreyee ; Harel, Ronen ; Steinberg, Amir</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c243t-94fd04755cea1836ac4e3a260d1035666f04913f883d71dc60f1b23fd2ac8bb23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Bone marrow</topic><topic>Case reports</topic><topic>Chemotherapy</topic><topic>Hematology</topic><topic>Inhibitor drugs</topic><topic>Leukemia</topic><topic>Monoclonal antibodies</topic><topic>Mutation</topic><topic>Oncology</topic><topic>Patients</topic><topic>Remission (Medicine)</topic><topic>Targeted cancer therapy</topic><topic>Thrombocytopenia</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vegunta, Rathnamitreyee</creatorcontrib><creatorcontrib>Harel, Ronen</creatorcontrib><creatorcontrib>Steinberg, Amir</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Curēus (Palo Alto, CA)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vegunta, Rathnamitreyee</au><au>Harel, Ronen</au><au>Steinberg, Amir</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Intensified-Dose Chemotherapy in Combination With Gemtuzumab-Ozogamicin for the Treatment of Favorable-Risk Acute Myeloid Leukemia (AML)</atitle><jtitle>Curēus (Palo Alto, CA)</jtitle><date>2022-06-23</date><risdate>2022</risdate><volume>14</volume><issue>6</issue><issn>2168-8184</issn><eissn>2168-8184</eissn><abstract>Chemotherapy has been the standard of treatment for acute myeloid leukemia (AML). With the emergence of new therapies for AML like gemtuzumab-ozogamicin and FLT3 inhibitors, such as sorafenib, midostaurin, and gilteritinib, the optimal dose of chemotherapy and safety profile in different age groups when combined with these new therapies is yet to be established. There are limited data on the treatment of AML by combining intensified daunorubicin (doses of 90 mg/m2) with gemtuzumab-ozogamicin (GO). We report a young adult with favorable-risk AML treated with daunorubicin at a dose of 90 mg/m2 combined with GO, who had a complete response after induction but had a profound nadir of platelet count after induction and consolidation.</abstract><cop>Palo Alto</cop><pub>Cureus Inc</pub><pmid>35898381</pmid><doi>10.7759/cureus.26240</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2168-8184 |
| ispartof | Curēus (Palo Alto, CA), 2022-06, Vol.14 (6) |
| issn | 2168-8184 2168-8184 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9308398 |
| source | PubMed Central Open Access; PubMed Central |
| subjects | Bone marrow Case reports Chemotherapy Hematology Inhibitor drugs Leukemia Monoclonal antibodies Mutation Oncology Patients Remission (Medicine) Targeted cancer therapy Thrombocytopenia |
| title | Intensified-Dose Chemotherapy in Combination With Gemtuzumab-Ozogamicin for the Treatment of Favorable-Risk Acute Myeloid Leukemia (AML) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T19%3A37%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Intensified-Dose%20Chemotherapy%20in%20Combination%20With%20Gemtuzumab-Ozogamicin%20for%20the%20Treatment%20of%20Favorable-Risk%20Acute%20Myeloid%20Leukemia%20(AML)&rft.jtitle=Cur%C4%93us%20(Palo%20Alto,%20CA)&rft.au=Vegunta,%20Rathnamitreyee&rft.date=2022-06-23&rft.volume=14&rft.issue=6&rft.issn=2168-8184&rft.eissn=2168-8184&rft_id=info:doi/10.7759/cureus.26240&rft_dat=%3Cproquest_pubme%3E2696787498%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2696787498&rft_id=info:pmid/35898381&rfr_iscdi=true |